Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:745019rdf:typepubmed:Citationlld:pubmed
pubmed-article:745019lifeskim:mentionsumls-concept:C0002658lld:lifeskim
pubmed-article:745019lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:745019lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:745019lifeskim:mentionsumls-concept:C0086130lld:lifeskim
pubmed-article:745019lifeskim:mentionsumls-concept:C0070559lld:lifeskim
pubmed-article:745019pubmed:issue3-4lld:pubmed
pubmed-article:745019pubmed:dateCreated1979-5-23lld:pubmed
pubmed-article:745019pubmed:abstractTextDeprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients. Phenylethylamine and amphetamine have been investigated using a gas chromatographic technique.lld:pubmed
pubmed-article:745019pubmed:languageenglld:pubmed
pubmed-article:745019pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:745019pubmed:citationSubsetIMlld:pubmed
pubmed-article:745019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:745019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:745019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:745019pubmed:statusMEDLINElld:pubmed
pubmed-article:745019pubmed:issn0300-9564lld:pubmed
pubmed-article:745019pubmed:authorpubmed-author:RiedererPPlld:pubmed
pubmed-article:745019pubmed:authorpubmed-author:SandlerMMlld:pubmed
pubmed-article:745019pubmed:authorpubmed-author:ReynoldsG PGPlld:pubmed
pubmed-article:745019pubmed:authorpubmed-author:JellingerKKlld:pubmed
pubmed-article:745019pubmed:authorpubmed-author:SeemannDDlld:pubmed
pubmed-article:745019pubmed:issnTypePrintlld:pubmed
pubmed-article:745019pubmed:volume43lld:pubmed
pubmed-article:745019pubmed:ownerNLMlld:pubmed
pubmed-article:745019pubmed:authorsCompleteYlld:pubmed
pubmed-article:745019pubmed:pagination271-7lld:pubmed
pubmed-article:745019pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-H...lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-B...lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-P...lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-P...lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-A...lld:pubmed
pubmed-article:745019pubmed:meshHeadingpubmed-meshheading:745019-S...lld:pubmed
pubmed-article:745019pubmed:year1978lld:pubmed
pubmed-article:745019pubmed:articleTitleAmphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.lld:pubmed
pubmed-article:745019pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:745019lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:745019lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:745019lld:pubmed